Alida Bio
San Diego, US · Founded 2020 · 4 known investors
Find your way into Alida Bio
99 people in our graph share verified history with the Alida Bio team — schools, employers, funds. One of them is your warm intro.
Alida Biosciences develops tools for RNA modification detection and analysis that enable research and diagnostic applications across drug discovery, clinical testing, and biotechnology. The company uses protein engineering and enzymology expertise to enable evaluation of RNA code beyond its primary sequence.
Founders & leadership
Alida Bio was founded in 2020 by Byron Purse.
Investors · 4
Reported raises · per SEC filings
Form D private placements$12M disclosed across 3 rounds · 2021–2024
▶$7.5MraisedJun 2024 · 3 investors · BiotechnologyRule 506(b)
- Landon MerrillDirector
- Gudrun StengelExecutive Officer, Director
- Paul ConleyDirector
- John DrewryDirector
- Offering amount
- $8.5M
- Amount sold
- $7.5M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$4MraisedMay 2022 · 2 investors · BiotechnologyRule 506(b)
- John DrewryDirector
- Gudrun StengelExecutive Officer, Director
- Paul ConleyDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$510KraisedJul 2021 · 4 investors · BiotechnologyRule 506(b)
- John DrewryDirector
- Gudrun StengelExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $510K
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $865.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $347.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $259.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $259.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $255K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Alida Bio do?
- Alida Biosciences develops tools for RNA modification detection and analysis that enable research and diagnostic applications across drug discovery, clinical testing, and biotechnology. The company uses protein engineering and enzymology expertise to enable evaluation of RNA code beyond its primary sequence.
- Who founded Alida Bio?
- Alida Bio was founded by Byron Purse in 2020.
- Who are Alida Bio's investors?
- Alida Bio's investors include FusionX Ventures, GENERAL INCEPTION, Vertical Venture Partners, Paladin Capital Group.
- How much funding has Alida Bio raised?
- Alida Bio has disclosed $12M raised across 3 rounds.
- Where is Alida Bio headquartered?
- Alida Bio is headquartered in San Diego, US.